OncoMatch/Clinical Trials/NCT04063527

Phase III Trial of Stage I Ovarian Cancer After Surgery

Is NCT04063527 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies adjuvant chemotherapy for epithelial ovarian cancer.

Phase 3RecruitingJapanese Gynecologic Oncology GroupNCT04063527Data as of May 2026

Treatment: adjuvant chemotherapy — To compare the Overall survival of adjuvant chemotherapy versus observation in stage I epithelial ovarian cancer after comprehensive staging surgery

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Disease stage

Required: Stage IA(GRADE2/3, CLEAR CELL CARCINOMA), IB(GRADE2/3, CLEAR CELL CARCINOMA), IC(B)(ALL DEGREE OF DIFFERENTIATION AND ALL HISTOLOGIC TYPE) (FIGO)

Excluded: Stage IC(A), IC(1), IC(2)

FIGO Stages Ia(Grade2/3, clear cell carcinoma), Ib(Grade2/3, clear cell carcinoma) and Ic(b)(all degree of differentiation and all histologic type)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify